Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Public Equity Financing	Palantir Technologies, Inc	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series X Redeemable Convertible Preferred Stock	Common Stock	Common Stock Public Equity Financing	Common Stock Palantir Technologies, Inc	Treasury Stock	Additional Paid-in Capital	Additional Paid-in Capital Public Equity Financing	Additional Paid-in Capital Palantir Technologies, Inc	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income
Balance at Dec. 31, 2020	$ (531,400)							$ 1			$ (256)	$ 32,418			$ (563,563)
Temporary Equity, Balance (in Shares) at Dec. 31, 2020					29,484,740	41,205,482	11,953,274
Temporary Equity, Balance at Dec. 31, 2020					$ 184,247	$ 290,866	$ 75,000
Balance (in Shares) at Dec. 31, 2020								18,529,453			(90,834)
Stock-based compensation expense	1,009											1,009
Net income (loss)	(81,539)														(81,539)
Balance at Mar. 31, 2021	(611,930)							$ 1			$ (256)	33,427			(645,102)
Balance (in Shares) at Mar. 31, 2021					29,484,740	41,205,482	11,953,274
Balance at Mar. 31, 2021					$ 184,247	$ 290,866	$ 75,000
Balance (in Shares) at Mar. 31, 2021								18,529,453			(90,834)
Balance at Dec. 31, 2020	(531,400)							$ 1			$ (256)	32,418			(563,563)
Temporary Equity, Balance (in Shares) at Dec. 31, 2020					29,484,740	41,205,482	11,953,274
Temporary Equity, Balance at Dec. 31, 2020					$ 184,247	$ 290,866	$ 75,000
Balance (in Shares) at Dec. 31, 2020								18,529,453			(90,834)
Net income (loss)	(96,078)
Balance at Sep. 30, 2021	96,216							$ 10				755,847			(659,641)
Balance (in Shares) at Sep. 30, 2021								123,464,113
Balance at Mar. 31, 2021	(611,930)							$ 1			$ (256)	33,427			(645,102)
Temporary Equity, Balance (in Shares) at Mar. 31, 2021					29,484,740	41,205,482	11,953,274
Temporary Equity, Balance at Mar. 31, 2021					$ 184,247	$ 290,866	$ 75,000
Balance (in Shares) at Mar. 31, 2021								18,529,453			(90,834)
Exercise of stock options	14											14
Exercise of stock options (in Shares)								3,711
Stock-based compensation expense	28,188											28,188
Net income (loss)	(64,477)														(64,477)
Balance at Jun. 30, 2021	(648,205)							$ 1			$ (256)	61,629			(709,579)
Balance (in Shares) at Jun. 30, 2021					29,484,740	41,205,482	11,953,274
Balance at Jun. 30, 2021					$ 184,247	$ 290,866	$ 75,000
Balance (in Shares) at Jun. 30, 2021								18,533,164			(90,834)
Recapitalization net of redemptions and equity issuance and merger costs redeemable convertible preferred stock (in Shares)					(29,484,740)	(41,205,482)	(11,953,274)
Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock					$ (184,247)	$ (290,866)	$ (75,000)
Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs (in Shares)								94,122,404			90,834
Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs	485,596							$ 8			$ 256	485,332
Equity classification of Legacy Celularity warrants	96,398											96,398
Issuance of common stock			$ 83,400	$ 20,000					$ 1				$ 83,399	$ 20,000
Issuance of common stock (in Shares)									8,340,000	2,000,000
Exercise of stock options	209											209
Exercise of stock options (in Shares)								468,545
Stock-based compensation expense	8,880											8,880
Net income (loss)	49,938														49,938
Balance at Sep. 30, 2021	96,216							$ 10				755,847			(659,641)
Balance (in Shares) at Sep. 30, 2021								123,464,113
Balance at Dec. 31, 2021	99,418							$ 12				763,087			(663,681)
Balance (Accounting Standards Update 2016-02) at Dec. 31, 2021		$ 3,996														$ 3,996
Balance (in Shares) at Dec. 31, 2021								124,307,884
Reclassification of previously exercised stock options	441											441
Stock issued during period shares reclassification of previously exercised stock options, in shares								131,253
Exercise of warrants	46,485							$ 2				46,483
Stock issued during period shares warrants exercised, in shares								13,281,386
Exercise of stock options	21											21
Exercise of stock options (in Shares)								10,255
Purchase and retirement of common shares, value	(11)											(11)
Purchase and retirement of common shares								(3,058)
Stock-based compensation expense	2,422											2,422
Net income (loss)	(62,867)														(62,867)
Balance at Mar. 31, 2022	89,905							$ 14				812,443			(722,552)
Balance (Accounting Standards Update 2016-02) at Mar. 31, 2022		(3)														(3)
Balance (in Shares) at Mar. 31, 2022								137,727,720
Balance at Dec. 31, 2021	99,418							$ 12				763,087			(663,681)
Balance (Accounting Standards Update 2016-02) at Dec. 31, 2021		3,996														3,996
Balance (in Shares) at Dec. 31, 2021								124,307,884
Net income (loss)	(10,242)
Balance at Sep. 30, 2022	164,235							$ 14				833,915			(669,930)		$ 236
Balance (in Shares) at Sep. 30, 2022								144,524,190
Balance at Mar. 31, 2022	89,905							$ 14				812,443			(722,552)
Balance (Accounting Standards Update 2016-02) at Mar. 31, 2022		$ (3)														$ (3)
Balance (in Shares) at Mar. 31, 2022								137,727,720
Issuance of common stock			$ 7,651										$ 7,651
Issuance of common stock (in Shares)									4,054,055
Exercise of warrants	4											4
Stock issued during period shares warrants exercised, in shares								304
Exercise of stock options	313											313
Exercise of stock options (in Shares)								609,529
Purchase and retirement of common shares, value	(75)											(75)
Purchase and retirement of common shares								(7,441)
Stock-based compensation expense	4,529											4,529
Net income (loss)	47,826														47,826
Balance at Jun. 30, 2022	150,150							$ 14				824,865			(674,729)
Balance (in Shares) at Jun. 30, 2022								142,384,167
Issuance of common stock	4,131											4,131
Issuance of common stock (in Shares)								1,817,830
Exercise of warrants	1											1
Stock issued during period shares warrants exercised, in shares								100
Exercise of stock options	399											399
Exercise of stock options (in Shares)								322,093
Stock-based compensation expense	4,519											4,519
Change in fair value of debt due to change in credit risk, net of tax	236																236
Net income (loss)	4,799														4,799
Balance at Sep. 30, 2022	$ 164,235							$ 14				$ 833,915			$ (669,930)		$ 236
Balance (in Shares) at Sep. 30, 2022								144,524,190